Eversept Partners LP Buys New Position in Assembly Biosciences, Inc. $ASMB

Eversept Partners LP bought a new stake in Assembly Biosciences, Inc. (NASDAQ:ASMB) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 159,676 shares of the biopharmaceutical company’s stock, valued at approximately $5,431,000. Eversept Partners LP owned about 1.01% of Assembly Biosciences at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in ASMB. Acadian Asset Management LLC boosted its holdings in Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after acquiring an additional 6,823 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Assembly Biosciences by 6.9% in the second quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company’s stock valued at $925,000 after acquiring an additional 3,312 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Assembly Biosciences by 97.8% in the third quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock valued at $12,854,000 after acquiring an additional 248,287 shares during the last quarter. Patient Square Capital LP bought a new stake in Assembly Biosciences in the third quarter valued at approximately $3,461,000. Finally, Palumbo Wealth Management LLC boosted its holdings in Assembly Biosciences by 86.4% in the third quarter. Palumbo Wealth Management LLC now owns 34,798 shares of the biopharmaceutical company’s stock valued at $891,000 after acquiring an additional 16,131 shares during the last quarter. 19.92% of the stock is currently owned by institutional investors.

Assembly Biosciences Stock Performance

Assembly Biosciences stock opened at $24.15 on Thursday. Assembly Biosciences, Inc. has a 52-week low of $16.50 and a 52-week high of $39.71. The stock’s 50 day moving average price is $27.32 and its two-hundred day moving average price is $29.15. The stock has a market capitalization of $383.74 million, a price-to-earnings ratio of -219.53 and a beta of 1.07.

Assembly Biosciences (NASDAQ:ASMB) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.11. Assembly Biosciences had a negative return on equity of 4.21% and a negative net margin of 8.98%.The company had revenue of $8.21 million for the quarter, compared to analyst estimates of $9.27 million. On average, equities research analysts forecast that Assembly Biosciences, Inc. will post 1.9 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on ASMB shares. Guggenheim reiterated a “buy” rating and issued a $43.00 target price on shares of Assembly Biosciences in a report on Thursday, May 28th. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Assembly Biosciences in a report on Monday, May 4th. Mizuho set a $45.00 price target on Assembly Biosciences and gave the stock an “outperform” rating in a report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Monday, April 20th. Finally, Wall Street Zen cut Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Assembly Biosciences presently has an average rating of “Moderate Buy” and an average price target of $44.00.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.